Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH -2.61%28 EV-to-OCF is -4.11 as of Jul. 25, 2026. GuruFocus rates ASX:ATH with a GF Score™ of 28/100. Among 1,410 Biotechnology companies, Alterity Therapeutics ranks better than 54.04% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alterity Therapeutics's Enterprise Value is A$72.70 Mil.
Alterity Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.71 Mil. Therefore, Alterity Therapeutics's EV-to-OCF for today is -4.11.
The historical rank and industry rank for Alterity Therapeutics's EV-to-OCF or its related term are showing as below:
ASX:ATH'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.11 Med: 0 Max: -4.11
Current: -4.11
During the past 13 years, the highest EV-to-OCF of Alterity Therapeutics was -4.11. The lowest was -4.11. And the median was .
ASX:ATH's EV-to-OCF is ranked better than 54.04% of 1410
companies
in the Biotechnology industry
Industry Median: -3.315
vs ASX:ATH: -4.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alterity Therapeutics's PE Ratio (TTM) for today is calculated as:
Alterity Therapeutics's share price for today is A$0.56.
Alterity Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alterity Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's EV-to-OCF falls into.
Alterity Therapeutics's current Enterprise Value is A$72.70 Mil.
Alterity Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-17.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alterity Therapeutics (ASX:ATH) has a EV-to-OCF of -4.11 as of Jul. 25, 2026. According to the industry distribution chart, Alterity Therapeutics ranks #648 out of 1410 companies in the Biotechnology industry, placing it in the top 46%.
Is Alterity Therapeutics' EV-to-OCF too high?
Alterity Therapeutics' current EV-to-OCF is -4.11. Based on the distribution chart, Alterity Therapeutics ranks #648 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #648 out of 1410 companies for EV-to-OCF. This puts Alterity Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alterity Therapeutics's current EV-to-OCF is -4.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current EV-to-OCF of -4.11. The current EV-to-OCF is -4.11. Alterity Therapeutics' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current EV-to-OCF is -4.11 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score
Get the complete analysis for ASX:ATH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
